C4 Therapeutics Net Worth
C4 Therapeutics Net Worth Breakdown | CCCC |
C4 Therapeutics Net Worth Analysis
C4 Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including C4 Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of C4 Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform C4 Therapeutics' net worth analysis. One common approach is to calculate C4 Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares C4 Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing C4 Therapeutics' net worth. This approach calculates the present value of C4 Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of C4 Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate C4 Therapeutics' net worth. This involves comparing C4 Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into C4 Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if C4 Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding C4 Therapeutics' net worth research are outlined below:
| C4 Therapeutics is way too risky over 90 days horizon | |
| C4 Therapeutics appears to be risky and price may revert if volatility continues | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (75.39 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (65.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: C4 Therapeutics Bets Big On Unproven Biotech Pipeline - Finimize |
C4 Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in C4 Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to C4 Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
C4 Therapeutics Target Price Consensus
CCCC target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. C4 Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Buy |
Most CCCC analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand CCCC stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of C4 Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationC4 Therapeutics Target Price Projection
C4 Therapeutics' current and average target prices are 2.32 and 13.75, respectively. The current price of C4 Therapeutics is the price at which C4 Therapeutics is currently trading. On the other hand, C4 Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
C4 Therapeutics Market Quote on 21st of July 2025
Target Price
Analyst Consensus On C4 Therapeutics Target Price
Know C4 Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as C4 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading C4 Therapeutics backward and forwards among themselves. C4 Therapeutics' institutional investor refers to the entity that pools money to purchase C4 Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 1.2 M | Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 1.1 M | Tang Capital Management Llc | 2025-03-31 | 900 K | Silverarc Capital Management, Llc | 2025-03-31 | 882.3 K | Ubs Group Ag | 2025-03-31 | 872.8 K | Two Sigma Advisers, Llc | 2025-03-31 | 800.6 K | Jacobs Levy Equity Management, Inc. | 2025-03-31 | 697.7 K | Goldman Sachs Group Inc | 2025-03-31 | 622.7 K | Wells Fargo & Co | 2025-03-31 | 523.6 K | Soleus Capital Management, L.p. | 2025-03-31 | 7 M | Orbimed Advisors, Llc | 2025-03-31 | 6.8 M |
Follow C4 Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 164.74 M.Market Cap |
|
Project C4 Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.49) | (0.46) |
When accessing C4 Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures C4 Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of C4 Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
Evaluate C4 Therapeutics' management efficiency
C4 Therapeutics has return on total asset (ROA) of (0.203) % which means that it has lost $0.203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4555) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of July 21, 2025, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.41. At present, C4 Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 274 M, whereas Net Tangible Assets are forecasted to decline to about 168.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.11 | 2.40 | |
| Tangible Book Value Per Share | 3.11 | 2.40 | |
| Enterprise Value Over EBITDA | (2.52) | (2.64) | |
| Price Book Value Ratio | 1.16 | 1.21 | |
| Enterprise Value Multiple | (2.52) | (2.64) | |
| Price Fair Value | 1.16 | 1.21 | |
| Enterprise Value | 258.6 M | 245.7 M |
C4 Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 0.3523 | Revenue | Quarterly Revenue Growth 1.382 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific C4 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on C4 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases C4 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
C4 Therapeutics time-series forecasting models is one of many C4 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary C4 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
C4 Therapeutics Earnings Estimation Breakdown
The calculation of C4 Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of C4 Therapeutics is estimated to be -0.40875 with the future projection ranging from a low of -0.4475 to a high of -0.38. Please be aware that this consensus of annual earnings estimates for C4 Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.45 Lowest | Expected EPS | -0.38 Highest |
C4 Therapeutics Earnings Projection Consensus
Suppose the current estimates of C4 Therapeutics' value are higher than the current market price of the C4 Therapeutics stock. In this case, investors may conclude that C4 Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and C4 Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 7 | 50.0% | 0.0 | -0.40875 | -1.48 |
C4 Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of C4 Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering C4 Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of C4 Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.C4 Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as C4 Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of C4 Therapeutics should always be considered in relation to other companies to make a more educated investment decision.CCCC Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact C4 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | -0.35 | -0.37 | -0.02 | 5 | ||
2025-02-20 | 2024-12-31 | -0.4504 | -0.49 | -0.0396 | 8 | ||
2024-10-31 | 2024-09-30 | -0.38 | -0.35 | 0.03 | 7 | ||
2024-08-01 | 2024-06-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2024-05-08 | 2024-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2024-02-22 | 2023-12-31 | -0.68 | -0.7 | -0.02 | 2 | ||
2023-11-01 | 2023-09-30 | -0.66 | -0.52 | 0.14 | 21 | ||
2023-08-08 | 2023-06-30 | -0.69 | -0.73 | -0.04 | 5 | ||
2023-05-04 | 2023-03-31 | -0.75 | -0.71 | 0.04 | 5 | ||
2023-02-23 | 2022-12-31 | -0.74 | -0.77 | -0.03 | 4 | ||
2022-11-03 | 2022-09-30 | -0.67 | -0.65 | 0.02 | 2 | ||
2022-08-04 | 2022-06-30 | -0.69 | -0.56 | 0.13 | 18 | ||
2022-05-05 | 2022-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2022-02-24 | 2021-12-31 | -0.58 | -0.31 | 0.27 | 46 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-08-11 | 2021-06-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-05-13 | 2021-03-31 | -0.63 | -0.49 | 0.14 | 22 | ||
2021-03-11 | 2020-12-31 | -0.53 | -0.04 | 0.49 | 92 | ||
2020-11-12 | 2020-09-30 | -0.79 | -17.55 | -16.76 | 2121 | ||
2020-09-02 | 2020-06-30 | 0 | -0.1 | -0.1 | 0 |
C4 Therapeutics Corporate Management
| Paige Mahaney | Chief Officer | Profile | |
| Kelly Schick | Chief Officer | Profile | |
| Isabel Chiu | Senior Development | Profile | |
| Mr MBA | Chief Officer | Profile | |
| Andrew Hirsch | Pres CEO | Profile | |
| Leonard MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth 1.382 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.